Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where William D. Shrader is active.

Publication


Featured researches published by William D. Shrader.


Structure | 2003

The Structure of the Extracellular Region of Human Hepsin Reveals a Serine Protease Domain and a Novel Scavenger Receptor Cysteine-Rich (SRCR) Domain

John R. Somoza; Joseph D. Ho; Christine Luong; Manjiri Ghate; Paul A. Sprengeler; Kyle Mortara; William D. Shrader; David Sperandio; Hedy Chan; Mary E. McGrath; Bradley A. Katz

Hepsin is an integral membrane protein that may participate in cell growth and in maintaining proper cell morphology and is overexpressed in a number of primary tumors. We have determined the 1.75 A resolution structure of the extracellular component of human hepsin. This structure includes a 255-residue trypsin-like serine protease domain and a 109-residue region that forms a novel, poorly conserved, scavenger receptor cysteine-rich (SRCR) domain. The two domains are associated with each other through a single disulfide bond and an extensive network of noncovalent interactions. The structure suggests how the extracellular region of hepsin may be positioned with respect to the plasma membrane.


Journal of Molecular Biology | 2003

Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.

Bradley A. Katz; Kyle Elrod; Erik Verner; Richard L. Mackman; Christine Luong; William D. Shrader; Martin Sendzik; Jeffrey R. Spencer; Paul A. Sprengeler; Aleks Kolesnikov; Vincent W.-F. Tai; Hon C. Hui; J.Guy Breitenbucher; Darin Allen; James W. Janc

An extensive structural manifold of short hydrogen bond-mediated, active site-directed, serine protease inhibition motifs is revealed in a set of over 300 crystal structures involving a large suite of small molecule inhibitors (2-(2-phenol)-indoles and 2-(2-phenol)-benzimidazoles) determined over a wide range of pH (3.5-11.4). The active site hydrogen-bonding mode was found to vary markedly with pH, with the steric and electronic properties of the inhibitor, and with the type of protease (trypsin, thrombin or urokinase type plasminogen activator (uPA)). The pH dependence of the active site hydrogen-bonding motif is often intricate, constituting a distinct fingerprint of each complex. Isosteric replacements or minor substitutions within the inhibitor that modulate the pK(a) of the phenol hydroxyl involved in short hydrogen bonding, or that affect steric interactions distal to the active site, can significantly shift the pH-dependent structural profile characteristic of the parent scaffold, or produce active site-binding motifs unique to the bound analog. Ionization equilibria at the active site associated with inhibitor binding are probed in a series of the protease-inhibitor complexes through analysis of the pH dependence of the structure and environment of the active site-binding groups involved in short hydrogen bond arrays. Structures determined at high pH (>11), suggest that the pK(a) of His57 is dramatically elevated, to a value as high as approximately 11 in certain complexes. K(i) values involving uPA and trypsin determined as a function of pH for a set of inhibitors show pronounced parabolic pH dependence, the pH for optimal inhibition governed by the pK(a) of the inhibitor phenol involved in short hydrogen bonds. Comparison of structures of trypsin, thrombin and uPA, each bound by the same inhibitor, highlights important structural variations in the S1 and active sites accessible for engineering notable selectivity into remarkably small molecules with low nanomolar K(i) values.


Bioorganic & Medicinal Chemistry Letters | 2006

Potent 4-amino-5-azaindole factor VIIa inhibitors

Huiyong Hu; Aleksandr Kolesnikov; Jennifer R. Riggs; Kieron E. Wesson; Robin Stephens; Ellen M. Leahy; William D. Shrader; Paul A. Sprengeler; Michael J. Green; Ellen Sanford; Margaret Nguyen; Erik Gjerstad; Ronnel Cabuslay; Wendy B. Young


Bioorganic & Medicinal Chemistry Letters | 2006

Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.

Wendy B. Young; Joyce Mordenti; Steven M. Torkelson; William D. Shrader; Aleksandr Kolesnikov; Roopa Rai; Liang Liu; Huiyong Hu; Ellen M. Leahy; Michael J. Green; Paul A. Sprengeler; Bradley A. Katz; Christine Yu; James W. Janc; Kyle Elrod; Ulla M. Marzec; Stephen R. Hanson


Bioorganic & Medicinal Chemistry Letters | 2006

Factor VIIa inhibitors: A prodrug strategy to improve oral bioavailability

Jennifer R. Riggs; Aleksandr Kolesnikov; John Hendrix; Wendy B. Young; William D. Shrader; Dange Vijaykumar; Robin Stephens; Liang Liu; Lin Pan; Joyce Mordenti; Michael J. Green; Juthamas Sukbuntherng


Bioorganic & Medicinal Chemistry Letters | 2006

Novel 5-azaindole factor VIIa inhibitors.

Jennifer R. Riggs; Huiyong Hu; Aleksandr Kolesnikov; Ellen M. Leahy; Kieron E. Wesson; William D. Shrader; Dange Vijaykumar; Troy A. Wahl; Zhiwei Tong; Paul A. Sprengeler; Michael J. Green; Christine Yu; Brad A. Katz; Ellen Sanford; Margaret Nguyen; Ronnel Cabuslay; Wendy B. Young


Bioorganic & Medicinal Chemistry Letters | 2006

Discovery of novel heterocyclic factor VIIa inhibitors

Roopa Rai; Aleksandr Kolesnikov; Paul A. Sprengeler; Steven M. Torkelson; Tony Ton; Bradley A. Katz; Christine Yu; John Hendrix; William D. Shrader; Robin Stephens; Ronnell Cabuslay; Ellen Sanford; Wendy B. Young


Bioorganic & Medicinal Chemistry Letters | 2006

Factor VIIa inhibitors: gaining selectivity within the trypsin family.

William D. Shrader; Aleksandr Kolesnikov; Jana Burgess-Henry; Roopa Rai; John Hendrix; Huiyong Hu; Steve Torkelson; Tony Ton; Wendy B. Young; Bradley A. Katz; Christine Yu; Jie Tang; Ronnel Cabuslay; Ellen Sanford; James W. Janc; Paul A. Sprengeler


Bioorganic & Medicinal Chemistry Letters | 2006

Factor VIIa inhibitors: improved pharmacokinetic parameters.

Aleksandr Kolesnikov; Roopa Rai; Wendy B. Young; Joyce Mordenti; Liang Liu; Steven M. Torkelson; William D. Shrader; Ellen M. Leahy; Huiyong Hu; Erik Gjerstad; James W. Janc; Bradley A. Katz; Paul A. Sprengeler


Bioorganic & Medicinal Chemistry Letters | 2006

Small molecule inhibitors of plasma kallikrein.

Wendy B. Young; Roopa Rai; William D. Shrader; Jana Burgess-Henry; Huiyong Hu; Kyle Elrod; Paul A. Sprengeler; Bradley A. Katz; Juthamas Sukbuntherng; Joyce Mordenti

Collaboration


Dive into the William D. Shrader's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge